検索結果
2008
Takeuchi, H. ,
Suzuki, T. ,
Uchida, H. ,
Nakajima, S. ,
Nomura, K. ,
Kikuchi, T. ,
Manki, H. ,
Watanabe, K. &
Kashima, H. ,
2008 10月 ,
In: Journal of clinical psychopharmacology. 28 ,
5 ,
p. 540-543 4 p. 研究成果: Article › 査読
Aripiprazole
100%
Antipsychotic Agents
67%
Schizophrenia
60%
Patient Preference
13%
Therapeutics
12%
Suzuki, T. ,
Uchida, H. ,
Watanabe, K. ,
Nakajima, S. ,
Nomura, K. ,
Takeuchi, H. ,
Tanabe, A. ,
Yagi, G. &
Kashima, H. ,
2008 8月 1 ,
In: Human Psychopharmacology. 23 ,
6 ,
p. 455-463 9 p. 研究成果: Article › 査読
Quetiapine Fumarate
100%
Polypharmacy
93%
Olanzapine
93%
Risperidone
92%
Antipsychotic Agents
70%
Suzuki, T. ,
Uchida, H. ,
Nomura, K. ,
Takeuchi, H. ,
Nakajima, S. ,
Tanabe, A. ,
Yagi, G. ,
Watanabe, K. &
Kashima, H. ,
2008 12月 ,
In: Schizophrenia Research. 106 ,
2-3 ,
p. 328-336 9 p. 研究成果: Article › 査読
Schizophrenia
100%
Equipment and Supplies
73%
Reality Testing
22%
Therapeutics
20%
Therapeutic Alliance
18%
1990
Inada, T. ,
Yagi, G. ,
Kamijima, K. ,
Ohnishi, K. ,
Kamisada, M. ,
Takamiya, M. ,
Nakajima, S. &
Rockhold, R. W. ,
1990 12月 ,
In: Acta Psychiatrica Scandinavica. 82 ,
6 ,
p. 404-407 4 p. 研究成果: Article › 査読
Tardive Dyskinesia
100%
Movement Disorders
28%
Dyskinesias
27%
Psychiatry
18%
Extremities
18%
1987
Kamisada, M. ,
Waki, Y. ,
Nakajima, S. ,
Inada, T. &
Tateyama, M. ,
1987 12月 1 ,
In: Psychiatria et Neurologia Japonica - Seishin Shinkeigaku Zasshi. 89 ,
9 ,
p. 703-712 10 p. 研究成果: Article › 査読
1984
Fujii, Y. ,
Tateyama, M. ,
Kamisada, M. ,
Tanoue, A. ,
Takamiya, M. ,
Nakajima, S. &
Itoh, H. ,
1984 6月 ,
In: Psychiatry and Clinical Neurosciences. 38 ,
2 ,
p. 121-136 16 p. 研究成果: Article › 査読
bromperidol
100%
Drug Administration Schedule
91%
Serum
24%
Methotrimeprazine
14%
Antiparkinson Agents
12%
1982
Itoh, H. ,
Tanoue, S. ,
Yagi, G. ,
Tateyama, M. ,
Kamisada, M. ,
Fujii, Y. ,
Takamiya, M. &
Nakajima, S. ,
1982 1月 ,
In: the keio journal of medicine. 31 ,
3 ,
p. 71-95 25 p. 研究成果: Article › 査読
Ceruletide
100%
Emotions
57%
ceruletide diethylamine
55%
Clinical Studies
50%
Clinical Trials
47%